Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma.
Liu Y, Zhan Z, Kang Z, Li M, Lv Y, Li S, Tong L, Feng F, Li Y, Zhang M, Xue Y, Chen Y, Zhang T, Song P, Su Y, Shen Y, Sun Y, Yang X, Chen Y, Yao S, Yang H, Wang C, Geng M, Li W, Duan W, Xie H, Ding J.
Liu Y, et al. Among authors: li s, li y, li w, li m.
Acta Pharm Sin B. 2023 Dec;13(12):4748-4764. doi: 10.1016/j.apsb.2023.09.009. Epub 2023 Sep 22.
Acta Pharm Sin B. 2023.
PMID: 38045044
Free PMC article.